Objective:To explore the correlation between phase angle, determined by bioelectrical impedance analysis, and common chronic metabolic diseases in centrally obese individuals, aiming to assess the role of phase angle as a potential biomarker in screening for and preventing common chronic metabolic diseases associated with central obesity.Methods:In this retrospectivel study, body composition measurement was conducted among centrally obese patients attending the outpatient clinic of the Department of Clinical Nutrition of the First Affiliated Hospital of Xinjiang Medical University from July 2022 to May 2024, along with the collection of current medical histories. The subjects were divided into three groups from Q1 to Q3 according to the tertiles of phase angle (Q1 group: phase angle<5.1°; Q2 group: phase angle≥5.1° but <5.6°; and Q3 group: phase angle>5.6°), and the prevalence of metabolic diseases and the differences in body compositions were compared among these three groups. Pearson's correlation was used to analyse the potential associations of phase angle and each body composition with common chronic metabolic diseases.Results:A total of 3 476 centrally obese individuals (1 141 males and 2 335 females) were included in the study. The Q1 group had significantly older age [(45.0±15.1) years vs. (36.1±10.0) years], higher prevalence of type 2 diabetes mellitus (T2DM) (23.9% vs. 17.3%), higher body fat percentage [(41.80%±6.36%) vs. (36.81%±7.21%)], and larger visceral fat area [(171.43±43.46) cm2 vs. (157.57±47.05) cm2] but significantly lower body mass index [(29.98±4.93) kg/m2 vs. (32.57±4.94) kg/m2], basal metabolic rate [(5 692.12±653.33) kJ/d vs. (6 809.04±923.49) kJ/d], skeletal muscle index [(7.16±0.86) kg/m2 vs. (8.60±0.94) kg/m2], body cell mass [(29.47±4.63)(38.18±6.70) kg], and waist-to-hip ratio [(0.972±0.069) vs. (0.977±0.063)] than the Q3 group (all P<0.001). However, there were no significant differences in the prevalence rates of hypertension and dyslipidemia among the three groups (all P>0.05). Among female centrally obese patients, those with all three metabolic diseases had significantly smaller phase angle (4.85°±0.54°) than those with 1-2 metabolic diseases (5.10°±0.62°) and those without metabolic diseases (5.17°±0.55°) (both P<0.001). Among T2DM patients receiving different treatment regimens, phase angle was significantly smaller in the insulin treatment group and the combined treatment group than in the lifestyle intervention group and oral hypoglycemic medication group (all P<0.05). Conclusions:Phase angle is an effective indicator of T2DM in centrally obese individuals and has potential clinical value in the screening and evaluation of metabolic diseases in centrally obese individuals.

Objective:To compare the medical costs of using standard fortified donor human milk (DHM) or preterm formula (PF) to supply very low birth weight [VLBW, defined as birth weight (BW) ≥1 000 g but <1 500 g] and extremely low birth weight (ELBW, defined as BW <1 000 g) premature infants with insufficient maternal breast milk.Methods:VLBW and ELBW preterm infants hospitalized in Peking Union Medical College Hospital from September 2017 to October 2020 were retrospectively enrolled and assigned into DHM group and PF group based on complementary feeding methods. The cost of parenteral nutrition (PN), cost of antibiotics, and total medical expenses during hospitalization were compared between the two groups.Results:A total of 89 infants were enrolled in this study, out of whom 50 was in the DHM group and 39 the PF group. The gestational age in DHM group and PF group were both (29±2) weeks. The BW of DHM group was 1 170 (919, 1 380)?g and that of PF group was 1 170 (1 010, 1 360) g. There were no significant differences in gestational age, BW, maternal age at delivery, delivery mode, gender ratio, proportion of small-for-gestational-age infants and length of hospital stay between the two groups (all P>0.05). The cost of parenteral nutrition in DHM group was significantly lower than that in PF group [3 500 (1 922, 5 704) Chinese yuan vs 7 995 (5 579, 10 788) Chinese Yuan, P<0.01]. The cost of antibiotics in DHM group was significantly lower than that in PF group [6 529 (2 265, 10 860) Chinese Yuan vs 13 676 (10 480, 18 506) Chinese Yuan, P<0.01]. The difference in total medical expense during hospitalization showed no statistical significance between two groups ( P>0.05). Amorg VLBW preterm infants, the cost of PN, cost of antibiotics, total cost of hospitalization, and daily cost of hospitalization in HDM group was significantly lower than that in PF group (all P<0.05). In ELBW preterm infants, the cost of PN and the cost of antibiotics in HDM group were significantly lower than that in PF group (both P<0.05), but the total cost of hospitalization and the daily cost of hospitalization between two groups showed no significant difference (all P>0.05). Conclusions:When mother's own milk is insufficient, using donor human milk reduces the costs of PN and antibiotics in VLBW and ELBW preterm infants compared with using PF. In VLBW preterm infants, using DHM can also reduce the total and daily cost of hospitalization.

Objective:To systematically evaluate the effect of the Dietary Approaches to Stop Hypertension (DASH) diet on common metabolic diseases.Methods:Following the PICOS framework to construct the search formula, we systematically searched the Web of science, PubMed, Cochrane Library, CNKI, Wanfang, and VIP databases for randomized controlled trials (RCTs) investigating the effect of the DASH diet on multiple metabolic indices including body weight, body mass index (BMI), fasting blood glucose, triglycerides, systolic blood pressure (SBP), and diastolic blood pressure (DBP) in patients with metabolic disorders (e.g., obesity, diabetes mellitus, and hypertension) published both in China and abroad from 1 January 2000 to 31 December 2023. The search terms were combinations of MeSH and free-text terms, and the raw data obtained from the search were screened according to the inclusion and exclusion criteria to determine the articles that were finally included in the analysis. The differences in these metabolic indices were compared between the intervention group group (using DASH diet) and the control group. The quality of the studies was assessed quantitatively using the modified Jadad scale and qualitatively using the Risk of Bias 2 (RoB 2) tool by two reviewers independently. Data analysis was conducted using Stata 18.0 software, with the I 2 test for heterogeneity evaluation and funnel plots for qualitative assessment of publication bias. Results:A total of 13 RCTs were included, involving 1 653 participants. Meta-analysis showed that the intervention group had more favorable effects on SBP ( SMD:-0.91, 95%CI: -1.55–-0.27; Z=-2.79, P<0.005) and DBP ( SMD: -0.98, 95%CI: -1.62–-0.33; Z=-2.96, P<0.05) than the control diet. Fasting blood glucose ( SMD: 0.21, 95% CI: 0.01–0.41; Z=2.06, P=0.04) was statistically significant. There were no significant differences in body weight, BMI, fasting blood glucose, and triglyceride outcomes betweeen these two groups. Conclusions:DASH diet is effective in controlling SBP and DBP in patients with metabolic disorders and may be useful in clinical adjunctive therapy. However, current evidence does not support an independent improvement in glycolipid metabolic markers.

Metabolic and bariatric surgery (MBS) is an effective treatment for obesity as it can dramatically reduce body weight and improve obesity-related comorbidities. However, postoperative changes from MBS can impair gastrointestinal structure and function, leading to micronutrient (MN) deficiencies and potentially severe organ dysfunction. MNs, including vitamins and trace elements, are crucial for human metabolism and can influence disease progression and outcomes. By reviewing the domestic and international literature in the past 5 years, we summarized and analyzed MN changles and nutritional management after various MBS procedures, aiming to further inform clinical practice.

Uremic toxin accumulation is the main factor that aggravates renal injury and increases complication risks in patients with chronic kidney disease (CKD). While renal replacement therapy such as hemodialysis and peritoneal dialysis are the mainstay of treatment for uremia, they have a limited role in clearing enterogenous uremic toxins, which are produced by gut flora catabolizing food nutrients. Gut flora dysbiosis is one of the common complications in CKD patients. As microecological preparations, probiotics, prebiotics and synbiotics can improve the clinical symptoms and quality of life in such patients through regulating the imbalance of gut flora. This article reviews the recent progress on the roles and mechanisms of these microecological preparations in patients with CKD.

Objective:To explore the research characteristics of clinical nutrition in China across different periods by systematically analyzing the articles published in the Chinese Journal of Clinical Nutrition over three decades (1993–2024). Methods:We utilized the bibliometric tool VOSviewer to divide the articles published in the Chinese Journal of Clinical Nutrition from 1993 to 2024 into three stages: 1993–2001, 2002–2008, and 2009–2024, for which every two consecutive editorial boards were regarded as one stage. Keyword co-occurrence analysis was conducted and the authors were analyzed. Accordingly, knowledge graphs were drawn to reflect the research characteristics of clinical nutrition in China at various developmental stages. Results:Research on clinical nutrition research in China differed across different stages. From 1993 to 2001, research primarily focused on parenteral and enteral nutrition and nutritional support, exploring their applications for specific diseases. From 2002 to 2008, the content of research became more detailed, and evidence-based methodologies were widely adopted, promoting the transition of research from simple nutrition support to the analysis of nutrition intervention mechanisms and evidence-based practice. From 2009 to 2024, articles published in the Chinese Journal of Clinical Nutrition not only focused on traditional nutritional support and disease interventions but also introduced emerging standards and new diseases, involving more diseases and populations; additionally, the research hotspots extended to interdisciplinary fields, along with continuously evolved research methods and technologies. Conclusions:The evolution of articles published in the Chinese Journal of Clinical Nutrition over the past 32 years not only documented the developmental trajectory of Chinese clinical nutrition from basic technical specifications to precision medicine interventions but also offered a paradigm shift of the discipline from the introduction and digestion of technologies to the independent innovation in formulating clinical nutrition-related guidelines and expert consensuses.

Objective:An inceasing number of commercial multi-chambered bag products for parenteral nutrition (PN) have been launched in China, with some being included in the National Medical Insurance Catalogue (NMIC). In this study, the commercially available triple-chambered bag (3CB) products for PN in China were comprehensively analyzed in terms of basic characteristics, applicable population, and costs to guide the rational use of these products in clinical settings.Methods:The marketing information of 3CB products was collected. The inclusion of these products in NMIC and the Catalogue of Selected Drugs for National Centralized Procurement was investigated, along with the collection of manufacturer's instructions and pricing information in Beijing. Two researchers extracted and calculated the information of 3CB products, including energy density, types and levels of each component, glycolipid ratio, osmotic pressure, and price. The applicable population and economy of these products were also compared.Results:As of April 2024, 11 3CB products, including 23 specifications, had been approved in China. Eight products were included by NMIC and 2 by the Catalogue of Selected Drugs for National Centralized Procurement. The energy density, protein content, and lipid content dramatically differed among 3CB products (energy density, 254.0–493.7 kJ/100 ml; protein, 2.2–5.6 g/100ml; lipid, 2–4 g/100 ml; and glycolipid ratio, 62∶38–40∶60). Five products could only be infused via the central veins. The sources of fat emulsions included soybean oil-based long-chain fat-milk, medium-long-chain fat-milk, olive oil-based fat-milk, and fish oil-based fat-milk. All the 3CB products contained 8 essential amino acids and some non-essential amino acids, with or without tyrosine, taurine, aspartic acid, and glutamic acid. The average daily total cost of 3CB PN was 74.78–585.82 yuan. Since Some 3CB products had been listed in NMIC, they were affordable for urban patients covered by Urban Employee Basic Medical Insurance but might be economically unacceptable for rural residents who are insured by the Basic Medical Insurance for Urban and Rural Residents and uninsured patients. Conclusions:A variety of 3CB products have been commercially available in China and can meet the individual PN needs of most patients. Although some products have been listed by NMIC, the economic burden can be heavy for certain patient populations.

Objective:To investigate the impacts of 1,25-dihydroxyvitamin D 3 (VD) and Lactobacillus plantarum (LP) on intestinal flora in animals with metabolic dysfunction-associated fatty liver disease (MAFLD) and their possible mechanisms. Methods:A methionine- choline-deficient (MCD) diet-induced rat model of MAFLD was created. Forty 10-week-old male Sprague-Dawley rats were randomized into methionine-choline-sufficient (MCS) group, MCD group, VD group, LP group, and VD-LP group, with 8 rats in each group. The intervention groups (VD group, LP group, and VD-LP group) were gastrically fed with VD peanut oil solution (6 ng/100 g daily), Lactobacillus plantarum solution (2×10 9CFU/100 g daily), and a combination of these two solutions, respectively. MCS group, MCD group, and LP group were given the same volume of peanut oil on a daily basis. Fecal samples from rats were collected at week 4 and analyzed using 16S rRNA gene sequencing for fecal flora structure. Portal vein blood samples were collected to detect liver biochemistry and lipopolysaccharide (LPS) levels. Pathological changes in liver and terminal ileum tissues were observed using hematoxylin and eosin (H&E) staining. Results:Compared with the MCS group, the MCD group exhibited massive steatosis and lipid infiltration in liver tissues, markedly thinned ileum mucosa, severely damaged villi structure, excessive necrotic and shedding of epithelial cells, and infiltration of inflammatory cells. Compared with the histopathological changes in the MCD group, the steatosis and lipid infiltration of liver tissue, the damage to the ileal mucosa structure and epithelial cells, and the infiltration of inflammatory cells were alleviated in the VD group, LP group, and VD-LP group. Compared with MCS group, the MCD group had significantly higher serum alanine aminotransferase (ALT) (158.50±14.03 U/L vs. 20.38±7.39 U/L), aspartate aminotransferase (AST) (43.88±11.36 U/L vs. 25.75±5.90 U/L), total bile acid (TBA) (140.60±11.77 μmol/L vs. 19.96±4.31 μmol/L), and LPS (16.57±1.19 pg/ml vs. 7.43±0.95 pg/ml) (All P<0.001),which confirmed the successful establishment of rat models of MAFLD. Serum ALT, AST, TBA, and LPS levels in all the three intervention groups were significantly lower than those in MCD group, and the most significant reductions in ALT (51.38±9.05 U/L vs. 158.50±14.03 U/L), AST (55.88±12.19 U/L vs. 143.88±11.36 U/L), TBA (21.00±8.17 μmol/L vs. 140.60±11.77 μmol/L), and LPS (9.72±0.71 pg/ml vs. 16.57±1.19 pg/ml) were seen in the VD-LP group. The microbiota in the MCD group predominantly featured Muribaculaceae, while the MCS group and other intervention groups primarily harbored Lactobacillus. Firmicutes and Lactobacillus were significantly decreased in the MCD group ,while Bacteroidete, Proteobacteria, Verrucomicrobiota, Prevotellaceae UCG-003, Escherichia coli, Bacteroides, and Enterococcus increased significantly. The opposite was true for each intervention group. There were significant differences in Lactobacillus between MCD group and the other four groups. Conclusion:VD and LP can remarkably improve lipid deposition in MAFLD by regulating intestinal flora.

Gut microorganisms are central to the intestinal microecosystem, regulating digestive functions and related to immune regulation, metabolic disorders, and nervous system development. Recent studies reveal the multifaceted interactions between micronutrients (MNs) and gut microbiota, where MNs provide essential nutrients to the intestinal flora and influence the production and absorption of various MNs through direct or indirect pathways. This article reviews the recent advances in the effects of water-soluble vitamins, fat-soluble vitamins, and micronutrients on the intestinal microecology, aiming to provide new ideas for future research.

Objective:To evaluate the impact of a high-energy-density, high-protein, immune-modulating, cancer-specific foods for special medical purposes (FSMP) on nutritional adequacy, safety, and efficacy in postoperative cancer patients.Methods:This multicenter randomized controlled trial enrolled patients with gastrointestinal or head and neck cancer scheduled for surgery and at nutritional risk. Participants were randomized 1∶1 to receive either the investigational cancer-specific FSMP (FSMP group) or a commercially available tumor-specific enteral nutrition (EN) formula (control group). The "nutritional transition phase" (postoperative days 0-3) provided the assigned EN, with energy deficits supplemented by parenteral nutrition (PN). This was followed by the "full EN phase" (intervention period: 10±3 days), with a target energy intake of 105-146 kJ/kg/day. Nutritional adequacy was considered achieved if the actual intake reached ≥80% of the target in both phases. The primary outcomes were the body weight and prealbumin improvement rates after intervention , and the secondary outcomes were the improvement rates of handgrip strength, gait speed, serum albumin, and hemoglobin. Non-inferiority was tested using the confidence intervals, with the least squares mean difference and its 95% CI derived from a Logistic regression model (non-inferiority margin: -0.12).Results:A total of 220 patients from 17 centers completed the study (FSMP group: n=109; control group: n=111). After the nutrition support, the weight loss was (-0.9±2.1) kg and (-1.3±1.8) kg in the FSMP and control groups ( P=0.162), whereas prealbumin increased in both groups (59.0±69.0 mg/L vs. 50.0±62.0 mg/L, P=0.418). The lower bounds of the 95% CIs were -0.08 for both weight and prealbumin improvement rates, exceeding the predefined non-inferiority margin (-0.12). No significant differences were observed in the improvements in albumin, hemoglobin, handgrip strength, or gait speed (all P>0.05). No serious adverse events related to the formulas occurred. The FSMP group had a higher incidence of diarrhea (31.9% vs. 17.8%) and lower compliance rate (<80% intake: 13.4% vs. 5.9%), but the percentages of total energy intake over the estimated energy requirements (% of target) were comparable (89.9%±24.5% vs. 94.0%±22.3%, P=0.310). Conclusions:The cancer-specific FSMP can improve postoperative nutritional status in cancer patients, demonstrating non-inferiority to existing tumor-specific EN formulas in terms of nutritional adequacy, safety, and efficacy.